Improvement of Molecular Genetic Testing in Russia

Partnership objectives

  1. Provide Russian cancer patients and health workers with the knowledge, information and tools to make informed treatment decisions in mCRC through the availability of molecular genetic testing.
  2. Raise awareness among stakeholders for the need for expanded access to cancer molecular genetic testing in mCRC.

Close to 6,500 patients have received testing and 7 labs have been validated for RAS testing in Moscow, St Petersburg, Novosibirsk and Vladivostok. Close to 6,500 patients have received testing and 7 labs have been validated for RAS testing in Moscow, St Petersburg, Novosibirsk and Vladivostok. Copyright Russco

What are the health needs and challenges?

According to Moscow Research Oncological Institute 2012 report, some 130,000 patients in Russia have CRC, and approximately 26% have metastic colorectoral cancer (mCRC.) The impact of CRC on population health is underestimated, largely due to the lack of a national screening program and limited access to innovative drugs and treatment. Colorectoral cancer is an increasing problem in the Russian Federation, which has the largest incidence of CRC among the BRICS (Brazil, Russia, India, China and South Africa).

Description of partnership activities and how they address needs and challenges

Since 2011, Merck Serono, the pharmaceutical division of Merck, has been supporting the RUSSCO (Interregional Public Organization 'Society of Medical Oncologists') program 'Improvement of the molecular genetic testing in the Russian Federation'.  The objective of the program is to make RAS testing available for patients with metastatic colorectal cancer across Russia. In the 2006 treatment guidelines for CRC, RAS testing was neither included nor was the cost of testing covered by mandatory health insurance. This program has helped draw attention of Russian government officials to CRC issues. To date, almost 6,500 patients have received RAS testing for genetic mutations. In addition, Merck is running the External Quality Insurance Project in cooperation with Pathology Institute of MLU, Munich through which 7 labs have successfully been validated for RAS testing.

Summary of impact and forward looking information

Close to 6,500 patients have received testing and 7 labs have been validated for RAS testing in Moscow, St Petersburg, Novosibirsk and Vladivostok.

Partnership information

Company(ies) Merck

Partner(s) Russian Society of Medical Oncologists (RUSSCO)

Type of Partner(s) Professional Associations

Therapeutic Focus Non-Communicable Diseases

Disease(s) Cancer

Program Type(s) Availability of Treatment - NCDs Access Programs, Prevention Programs - Awareness & Outreach

Targeted Population(s) General population

Region(s) Europe & Central Asia

Number of Countries 1

Country(ies) Russia

Start Date 2011

More information Cancer Genome (RU)

Anticipated completion date Ongoing